Cantor Fitzgerald’s Sarepta Therapeutics SRPT Stock Holding History

Cantor Fitzgerald’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,750	Closed	-$213K	–	389
2024 Q4	$213K	Buy	+1,750	New	+$214K	﹤0.01%	182
2024 Q3	–	Sell	-5,800	Closed	-$916K	–	300
2024 Q2	$916K	Buy	+5,800	New	+$745K	0.18%	80
2023 Q2	–	Sell	-52,984	Closed	-$7.3M	–	650
2023 Q1	$7.3M	Buy	52,984 +8,380	+19%	+$1.09M	0.16%	202
2022 Q4	$5.78M	Hold	44,604	–	–	0.12%	225
2022 Q3	$4.93M	Sell	44,604 -63,590	-59%	-$6.41M	0.11%	232
2022 Q2	$8.11M	Buy	+108,194	New	+$7.96M	0.16%	181

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cantor Fitzgerald's SRPT Position: Q1 2025 in Review

Cantor Fitzgerald sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 1,750 shares — an estimated $213K sold.

Cantor Fitzgerald first reported a position in SRPT in Q2 2022 and held it in 6 quarters. The position peaked at $8.11M in Q2 2022. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Cantor Fitzgerald reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Cantor Fitzgerald sold 1,750 Sarepta Therapeutics shares in Q1 2025, an estimated $213K.
Cantor Fitzgerald first reported a position in Sarepta Therapeutics in Q2 2022 and held it in 6 quarters.
Cantor Fitzgerald's Sarepta Therapeutics position peaked at $8.11M in Q2 2022.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Cantor Fitzgerald's 13F filing for Q1 2025, filed 15 May 2025.